Histological validation of a type 1 diabetes clinical diagnostic model for classification of diabetes by Carr, A. L. J. et al.
Research: Pathophysiology
Histological validation of a type 1 diabetes clinical
diagnostic model for classification of diabetes
A. L. J. Carr1, D. J. Perry2, A. L. Lynam1, S. Chamala2, C. S. Flaxman1, S. A. Sharp1,
L. A. Ferrat1, A. G. Jones1 , M. L. Beery2, L. M. Jacobsen3, C. H. Wasserfall2,
M. L. Campbell-Thompson2, I. Kusmartseva2, A. Posgai2, D. A. Schatz3, M. A. Atkinson2,3,
T. M. Brusko2, S. J. Richardson1,*, B. M. Shields1,* and R. A. Oram1,*
1Institute of Biomedical and Clinical Science, University of ExeterMedical School, Exeter, UK, 2Department of Pathology, Immunology and Laboratory Medicine and
3Department of Pediatrics, College ofMedicine, University of Florida Diabetes Institute, Gainesville, FL, USA
Accepted 1 July 2020
Abstract
Aims Misclassification of diabetes is common due to an overlap in the clinical features of type 1 and type 2 diabetes.
Combined diagnostic models incorporating clinical and biomarker information have recently been developed that can
aid classification, but they have not been validated using pancreatic pathology. We evaluated a clinical diagnostic model
against histologically defined type 1 diabetes.
Methods We classified cases from the Network for Pancreatic Organ donors with Diabetes (nPOD) biobank as type 1
(n = 111) or non-type 1 (n = 42) diabetes using histopathology. Type 1 diabetes was defined by lobular loss of insulin-
containing islets along with multiple insulin-deficient islets. We assessed the discriminative performance of previously
described type 1 diabetes diagnostic models, based on clinical features (age at diagnosis, BMI) and biomarker data
[autoantibodies, type 1 diabetes genetic risk score (T1D-GRS)], and singular features for identifying type 1 diabetes by
the area under the curve of the receiver operator characteristic (AUC-ROC).
Results Diagnostic models validated well against histologically defined type 1 diabetes. The model combining clinical
features, islet autoantibodies and T1D-GRS was strongly discriminative of type 1 diabetes, and performed better than
clinical features alone (AUC-ROC 0.97 vs. 0.95; P = 0.03). Histological classification of type 1 diabetes was concordant
with serum C-peptide [median < 17 pmol/l (limit of detection) vs. 1037 pmol/l in non-type 1 diabetes; P < 0.0001].
Conclusions Our study provides robust histological evidence that a clinical diagnostic model, combining clinical
features and biomarkers, could improve diabetes classification. Our study also provides reassurance that a C-peptide-
based definition of type 1 diabetes is an appropriate surrogate outcome that can be used in large clinical studies where
histological definition is impossible.
Parts of this study were presented in abstract form at the Network for Pancreatic Organ Donors Conference, Florida,
USA, 19–22 February 2019 and Diabetes UK Professional Conference, Liverpool, UK, 6–8 March 2019.
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Introduction
Correct classification of diabetes type is crucial for appropriate
management reduction of long-term complications. A funda-
mental difference between type 1 and type 2 diabetes is that the
former is characterized by rapid progression to endogenous
insulin deficiency due to autoimmune b-cell destruction. This
difference forms the basis of differences in their treatment and
management [1–3], however, this aetiopathological definition
is difficult to apply in clinical practice.
Clinical features are predominately used for classification of
diabetes type, with only age at diagnosis and BMI having
evidence for clinical utility at onset [4].Rising obesity rates and
type 2 diabetes in young people, and the incidence of type 1
diabetes throughout life [5–7] mean that misclassification of
diabetes is common, occurring in 7–15% of cases [4].
Although measurement of islet autoantibodies can assist
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classification, they are not perfectly discriminatory as some
people with type 1 diabetes do not have islet autoantibodies
and although relatively rare, autoantibodies positivity can
occur in type 2 diabetes [8]. Type 1 diabetes genetic risk scores
(T1D-GRS) have recently been shown to assist in discriminat-
ing between type 1, type 2 and other forms of diabetes in
research settings [9,10]. Studies such as the SEARCH for
Diabetes in Youth have developed classification criteria that
are helpful in guiding diabetes classification at diagnosis and
have informed international guidelines [11], but a difficulty
with all of these studies is which standard to validate against,
and that current guidelines are unable to provide simple
criteria that will always ensure correct diagnosis [1–3].
Wehave shown previously that both clinical features [12] and
biomarkers, such as autoantibodies and T1D-GRS, are most
discriminative of diabetes type when combined and modelled
continuously in diagnostic models that can be made widely
availableasanapporwebcalculator [4,9,13].Thesemodelswere
developed and validated onC-peptide-defined type 1 and type 2
diabetes,representingdifferences inendogenousinsulinsecretion
between the two types. A pilot version of our recently published
model is available online (https://www.diabetesgenes.org/t1d
t2d-prediction-model/). Measurement of C-peptide allows
robust diagnosis of type 1 diabetes in long-standing diabetes
(> 3 years’ duration) and closely relates to treatment require-
ments [14]. A strength of using C-peptide as an outcome is that,
irrespective of any assumptions about aetiology, progression to
lowC-peptide associates very stronglywith insulin requirement.
An alternative ‘gold standard’ would be pancreatic histol-
ogy, informed by internationally accepted histological criteria
[15]. Many other human diseases use histology as a gold
standard, but this is not available in living people with
diabetes due to the dangers of pancreatic biopsy [16]. The
Network for Pancreatic Organ donors with Diabetes (nPOD)
is a unique collection of human pancreata from organ donors
with and without diabetes, including those with type 1 and
type 2 diabetes, as well as autoantibody-positive donors
without diabetes [17]. Using the nPOD biobank tissues and
associated metadata, we sought to validate the performance of
a previously developed clinical diagnostic model against
histologically defined insulin deficiency defining type 1
diabetes. It has never been possible to validate diabetes
classification against histology, and we aimed to take advan-
tage of the nPOD biobank tissues and associated metadata to
define a histological outcome which we have used to support
findings from clinical studies of living patients.
Research design and methods
We assessed the performance of our previously developed
diagnostic model based on clinical features (age at diagnosis
and BMI) and biomarker data [islet antigen 2 (IA2) and
glutamic acid decarboxylase (GAD) antibody status and
T1D-GRS] in a histologically defined cohort of type 1 and
non-type 1 diabetes from the nPOD biobank. We compared
model performance with the performance of individual
clinical features and biomarkers.
Study cohort
We identified 221 nPOD diabetes cases with native pancreas
available and complete nPOD online pathology. We
excluded four cases with known monogenic forms [18] and
11 with secondary causes of diabetes, because the model was
designed to discriminate type 1 diabetes from type 2 diabetes.
We excluded 53 cases due to incomplete biomarker or
clinical information (BMI, age at diagnosis, IA2 and GAD
antibody status, T1D-GRS). We categorized diabetes and
analysed diagnostic model performance in the remaining 153
cases (Fig. 1). Clinical history, histopathology notes and slide
digitization were available through nPOD as described
previously [17]. A summary of characteristics for this cohort
is shown in Table 1.
Histological definition of type 1 and non-type 1 diabetes
We categorized diabetes as type 1 (n = 111) or non-type 1
(n = 42) using visualization of digitized slides via nPOD
online pathology database and/or nPOD pancreas material
held in Exeter, which were stained for the presence of insulin
and/or glucagon using standard immunohistochemical
approaches, as described previously [19,20]. Slides were
double-stained for insulin/glucagon, or serial sections were
stained for insulin and glucagon respectively, where align-
ment of the two allowed identification of insulin-deficient
What’s new?
• Misclassification of diabetes at diagnosis is common
due to an overlap in the clinical features of type 1 and
type 2 diabetes.
• Combining clinical features and biomarkers in a diag-
nostic model improved discrimination of diabetes type,
defined by insulin deficiency (measured by C-peptide
assays), over use of any single characteristic.
• No diabetes classification studies have used pancreatic
histology to define type 1 diabetes.
• A diagnostic model, developed using diabetes type
defined by C-peptide level as an outcome, validates
against histologically defined insulin deficiency.
• C-peptide provides a robust surrogate definition of type
1 diabetes that can be used in diagnostic model
development.
• Our study provides the first histological evidence for a
clinical diagnostic model having utility to identify type
1 diabetes in clinical practice.
ª 2020 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK 2161
Research article DIABETICMedicine
islets. Histology was reviewed by two independent investi-
gators in Exeter. A minimum of two slices per pancreas
section (head, body or tail) per donor was reviewed. We
defined type 1 diabetes histologically by the lobular loss of
insulin-containing islets with the presence of multiple (> 10)
insulin-deficient islets. Non-type 1 diabetes was defined as
having no insulin-deficient islets across all viewed sections of
the pancreas [15]. Islets were defined as having > 10 insulin-
and/or glucagon-positive cells. As there is no internationally
agreed definition of type 2 diabetes, we did not attempt to
positively classify type 2 diabetes on histology.
Autoantibody measurement
Autoantibody positivity status was measured by nPOD
(Organ Procurement Organizations screening laboratories)
using a modified rapid enzyme-linked immunosorbent assay
(ELISA) kit (Kronus, Star, ID, USA) with internal calibration
on donor serum. Autoantibody-positive samples were re-
analysed with an ELISA kit (Kronus, Gainesville, FL, USA),
and at the nPOD autoantibody core for GAD antibody, IA2
antibody, micro Insulin Autoantibody and Zinc Transporter
8 Autoantibody by radioligand-binding assay (Denver, CO,
USA) [21] as described previously [22].
C-peptide measurement and DNA isolation
Sera were obtained during the donor-screening process and/
or at donor organ recovery. Donor C-peptide was
Histological non-Type 1 diabetes cases
N=42
Histological Type 1 diabetes cases
n=111
No Yes
nPOD diabetes* cases with native pancreas available and 
complete online pathology and model variables n=153
Presence of significant lobular loss of insulin-containing islets resulting 
in >10 insulin deficient islets:
*Excluding known monogenic forms (18) (n=4) and secondary causes of diabetes (n=11).
FIGURE 1 Flow diagram of histological cohort identification from nPOD diabetes cases, excluding known monogenic forms and secondary causes of
diabetes. All cases included had age at diagnosis, BMI, glutamic acid decarboxylase (GAD) antibody and islet antigen 2 (IA2) antibody status, and
type 1 diabetes genetic risk score (T1D-GRS) recorded.
Table 1 Characteristics of histologically defined cohort
Non-type 1
diabetes
(n = 42)
Type 1 diabetes
(n = 111)
BMI (kg/m2) 29.9 [27.5; 34.3] 24.3 [22; 26.6]
Age at onset (years) 37.5 [26.8; 52.3] 11.5 [6.25; 17.3]
Diabetes duration
(years)
10 [1; 15] 12 [6; 23]
Age of death (years) 48.2 [40; 59.3] 27.6 [19.5; 37.1]
Sex
Female 20 (48) 51 (46)
Male 22 (52) 60 (54)
Genetic risk score 0.23 [0.21; 0.26] 0.27 [0.25; 0.29]
C-peptide (pmol/l) 1037 [429; 2072] < 17* [< 17*;
< 17*]
Antibodies†
0 38 (91) 56 (51)
1 4 (10) 32 (29)
2 0 (0.0) 10 (9)
3 0 (0.0) 13 (12)
Race
African American 12 (29) 11 (10)
Asian 2 (4.8) 0 (0.0)
White European 20 (48) 91 (82)
Hispanic/Latino 8 (19) 9 (8.1)
Values are shown as median [25th; 75th percentiles] or n (%).
*Limit of detection.
†Islet autoantibodies counted include glutamic acid decarboxy-
lase antibodies, islet antigen 2 antibodies, and Zinc Transporter
8 Autoantibody. micro Insulin Autoantibody is not included in
this count as it is not a reliable marker of autoimmunity in
persons receiving exogenous insulin.
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determined at the Northwest Lipid Metabolism and Diabetes
Research Laboratories (S. Marcovina, University of Washing-
ton, Seattle, WA, USA) by a two-site immuno-enzymometeric
assayusingaTosoh2000auto-analyser (TOSOH,Biosciences,
Inc., San Francisco, CA, USA). C-peptide levels are reported in
pmol/l with 1000 pmol/l = 3 ng/ml. We did not perform a
primary analysis against C-peptide as an outcome because of
the interactionbetweenrenal failure (frequent inorgandonors)
and sample storage time (also less controlled in organ donors).
DNA was extracted from frozen spleen where available [17]
and analysed for type 1 diabetes genetic susceptibility on a
UFDIchip Axiom genotyping array (ThermoFisher Scientific,
Waltham,MA, USA) as described below.
T1D-GRS generation
The T1D-GRS was generated using 30 single nucleotide
polymorphisms (SNPs) either genotyped directly (n = 26)
or imputed (n = 4, imputation r2 > 0.90) from a custom
UFDIchip Axiom genotyping array from ThermoFisher Sci-
entific. In total, the array covers 974 650 unique variants.
UFDIchips were processed on an Affymetrix Gene
Titan instrument with external sample handling on
a BioMek FX dual arm robotic workstation. Genetic data
underwent standard quality control procedures at the SNP,
sample and plate levels using AxiomTM Analysis Suite 3.0
(ThermoFisher Scientific) set to default stringency thresh-
olds as recommended. Next, discrepancies were assessed
for genotyped Human Leukocyte Antigen (HLA) vs.
imputed four-digit HLA (AxiomTM HLA Analysis software),
as well as for genetic vs. reported sex. Samples that failed
QC or were discordant were discarded. Finally, samples
were imputed to the Human Reference Consortium (ver-
sion r1.1) using Michigan Imputation Server [23]. T1D-
GRS was calculated on the nPOD cohort as described
previously [9,24] and indicates type 1 diabetes risk as a
continuous variable.
Combined diagnostic model
We calculated the probability of type 1 diabetes on all 153
included cases using our previously developed diagnostic
model [13] (Table S1). We assessed performance of the
model against histologically defined type 1 diabetes in the
nPOD cohort. We tested the previously developed clinical
diagnostic model in four combinations:
1. Clinical features only (age at diagnosis + BMI);
2. Clinical features + T1D-GRS;
3. Clinical features + IA2 antibody + GAD antibody;
4. Clinical features + IA2 antibody + GAD antibody + T1D-
GRS.
The primary analysis was to assess the discriminative
power and calibration of the diagnostic model in nPOD. We
carried out a secondary sensitivity analysis in a white
European ancestry subgroup of the cohort diagnosed at
between 18 and 50 years of age, in line with the inclusion
criteria of the original model development cohort [13]
(N = 31, type 1 diabetes n = 19; Table S2).
All procedures were in accordance with federal guidelines
for organ donation and approved by the University of Florida
Institutional Review Board.
Statistical methods
Weassessed discriminative performance by estimating the area
under the curve of the receiver operator characteristic (AUC-
ROC). We used the integrated discrimination improvement
index (IDI) [25] to assess improvements in discrimination
slopes when adding in additional features. Calibration was
assessed by comparing observed proportions against predicted
probabilitiesusingcalibrationplotsandtheBrier score,wherea
score of 0 indicates that the model is completely accurate. We
tested for statistical evidence of miscalibration using the
Spiegelhalter z-test (P < 0.05 representing evidence of miscal-
ibration). All AUC-ROC analysis was performed using the
pROC package in R and AUC estimated with DeLong’s
algorithm. We used a two-tailed DeLong comparison of ROC
curves to test for significant improvement in discriminative
power against the clinical features only model. Calibration
analysis and statistics were performed using the Hmisc (Frank
E. Harrell Jr, https://cran.r-project.org/web/packages/Hmisc/
index.html) and rms (Frank E. Harrell Jr, https://cran.r-
project.org/web/packages/rms/index.html) packages in R.
Results
Individual clinical features or biomarkers are discriminative of
type 1 diabetes
Age at diagnosis, BMI, autoantibodies (GAD and IA2) and
T1D-GRS were all strong individual discriminators of type 1
diabetes when modelled continuously (Fig. 2). The discrim-
ination varied from an AUC-ROC of 0.71 for autoantibodies
to 0.93 for age at diagnosis. This highlights that no single
feature in isolation predicted histology perfectly.
Type 1 diabetes clinical diagnostic model validates well
against a histological gold standard
All combinations of the type 1 diabetes clinical diagnostic
model tested validated well against a histological definition
FIGURE 2 Comparative discrimination of type 1 diabetes and non-type 1 diabetes cases from the nPOD biobank. Receiver operating characteristic
(ROC) curve and corresponding area under the curve (AUC) statistics and distribution are shown for BMI (A,B), age at diagnosis (C,D),
autoantibody count (E,F) and type 1 diabetes genetic risk score (G,H).
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of type 1 diabetes. Model combination 4, using clinical
features continuously with the addition of IA2 and GAD
antibody status, as well as T1D-GRS offers better discrim-
ination than a model using clinical features only [AUC-ROC
= 0.97, 95% confidence interval (CI) 0.95–1.00 vs. 0.95,
95% CI 0.91–0.98; P = 0.03] (Fig. 3). Addition of either IA2
and GAD antibody status or T1D-GRS improved the
discrimination slope (IDI = 0.05, 95% CI 0.01–0.08;
IDI = 0.07, 95% CI 0.02–0.12) (Fig. S1).
The type 1 diabetes clinical diagnostic model calibrates well
The mean overall probabilities of type 1 diabetes in the
nPOD cohort for each combination of clinical diagnostic
model tested closely reflected the proportion of observed type
1 diabetes cases in the study (111 of 153, 73%) (Fig. S2)
indicating overall good calibration. We found no evidence of
miscalibration across all model combinations as indicated by
a low Brier score (B = 0.06–0.08) and non-significant
Spiegelhalter z-statistics (Z < 1.76) (Table S3).
Sensitivity analysis in white European subgroup diagnosed in
adulthood (18–50 years of age)
Results of a sensitivity analysis, using a white European
ancestry subgroup diagnosed at between 18 and 50 years of
age, showed equivalent discriminatory power for all varia-
tions of the type 1 diabetes clinical diagnostic model
(N = 31, type 1 diabetes = 19, AUC-ROC > 0.84)
(Fig. S3). A summary of characteristics for this subgroup is
shown in Table S2.
Characteristics of cases with discordant model classification
compared with histology
The distribution of probabilities of type 1 diabetes generated
by model combination 4 are outlined in Fig. 3(B). This
highlights that a clinical diagnostic model will give an output
that is a continuous distribution of probabilities, with a small
number of type 1 diabetes cases still having low probability
of type 1 diabetes and some without type 1 diabetes still
identified as having a high probability. We examined the
features of cases that had probabilities at the extreme
distributions of model combination 4: two cases with
histological type 1 diabetes who had a probability of type
1 diabetes < 25%; and three cases with histological non-type
1 diabetes who had a probability of type 1 diabetes > 75%.
The characteristics of these cases are outlined in Table S4.
Serum C-peptide levels in these cases matched the histolog-
ical classification (two with histological type 1 diabetes had
C-peptide < 30 pmol/l, and three with histological non-type
1 diabetes had C-peptide > 1000 pmol/l). Despite our
concerns about C-peptide storage and sampling in organ
donors, the observed serum C-peptide levels in type 1 vs.
non-type 1 diabetes in the whole cohort was significantly
different [median < 17 pmol/l (limit of detection) vs. median
1037 pmol/l; P < 0.0001) (Table 1).
Discussion
This is the first study to evaluate a clinical diagnostic model
against histological data. We have demonstrated that a
model developed previously to classify type 1 diabetes
defined by insulin deficiency, is discriminative of type 1
diabetes when using a histological outcome, not possible in
routine clinical care. We found that using a combined model
performed better than individual clinical features and
biomarkers in discriminating type 1 diabetes and non-type
1 diabetes donor cohorts. Our study contributes to the
evidence that diagnostic models combining clinical features
with at least one clinical biomarker could assist classification
of diabetes in clinical practice, and is already available as a
beta-version online (https://www.diabetesgenes.org/t1dt2d-
prediction-model/).
We previously demonstrated that a classification model,
which integrated genetic testing combined with multiple
(a)
(b)
non-Type 1 diabetes Type 1 diabetes
Ty
pe
 1
 d
ia
be
te
s
FIGURE 3 The discriminative ability of diagnostic model 4 combining
BMI, age at diagnosis, autoantibody status and type 1 diabetes genetic
risk score (T1D-GRS) to identify type 1 diabetes cases. Receiver
operating characteristic (ROC) curve and corresponding area under the
curve (AUC) statistics (A). A boxplot of model 4 predicted probabilities
of type 1 diabetes (B).
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continuous clinical variables, was effective at discriminating
maturity-onset diabetes of the young (MODY) from type 1
diabetes [12]. An advantage in identification of MODY is
that the outcome, a genetic mutation causing diabetes, is
often definitive, but there is less clarity on a standard
definition of type 1 and type 2 diabetes. In developing
diagnostic models for diabetes classification, we used pro-
gression to insulin deficiency, as measured by serum C-
peptide in long-standing diabetes (> 3 years’ duration), as a
surrogate marker of type 1 diabetes [9,13]. We assumed that
insulin deficiency, as defined by serum C-peptide
< 200 pmol/l at > 3 years post diagnosis, was an accurate
surrogate of type 1 diabetes [14]. This study provides
evidence that this assumption is valid, by showing that our
model developed on clinical data to predict C-peptide
deficiency near perfectly reflects histologically defined insulin
deficiency (a robust but rarely used definition of type 1
diabetes). This result is further reinforced by comparison of
C-peptide in type 1 and non-type 1 diabetes groups, which
was non-overlapping (Table 1). Clinically, one strength of a
model trained on severe insulin deficiency as an outcome is
that prediction of severe insulin deficiency has a clear
treatment implication, the requirement of exogenous impli-
cations.
We used histological criteria for type 1 diabetes based on
work by Campbell-Thompson et al. [15]. Our criteria focus
on insulin deficiency and the presence of insulin-deficient
islets as a hallmark of type 1 diabetes that is present in all
type 1 diabetes cases. The international consensus definition
of type 1 diabetes histology describes various exclusive
pathological features in the pancreas. These include the
presence of insulitis that is always accompanied by pseudoa-
trophic islets devoid of b cells [15]. However, the proportion
of inflamed islets declines over time such that it is seen most
readily in short duration type 1 diabetes donors (< 1 year)
[26]. As the majority of the nPOD donors had a longer
duration of disease, and the presence of insulin-deficient
islets is evidence of prior insulitis; we used the detection of
insulin-deficient islets as our key histopathological criterion
to define type 1 diabetes in this study.
We focused on the positive histological definition of type 1
diabetes rather than defining other diabetes types by histol-
ogy, and excluded cases that had a diabetes diagnosis of
monogenic diabetes or secondary causes of diabetes. The
clinical features of our non-type 1 diabetes group suggest that
this group is composed of predominantly type 2 diabetes,
however, there is much less consensus on the histology of
other diabetes types, including type 2 diabetes, and our
original model was designed with features that discriminate
type 1 from type 2 diabetes, such as age at diagnosis and
BMI. In the future it may be possible to develop an approach
that additionally classifies type 2 diabetes and less-common
diabetes types. This will require larger collections of non-
type 1 diabetes cases [27] to allow accurate characterization
of type 2 diabetes pancreatic features.
A notable limitation of our study is that the current
diagnostic model was developed using data derived primarily
from white Europeans between the ages of 18 and 50 years.
It is well documented that the incidence and prevalence of
type 1 and type 2 diabetes vary across demographic
subgroups [28,29]. It is also well accepted that the prior
prevalence of type 1 and type 2 diabetes varies with age, with
type 2 diabetes more likely to be diagnosed at older ages and
type 1 diabetes more likely to be diagnosed at younger ages.
Our cohort included 27% non-white Europeans and age at
diagnosis ranged from 1 to 73 years, yet despite this, the
model showed good discrimination and calibrated well
overall (Table S3). Owing to the limitations of the sample
size in our study, further validation evidence of the model
performance is still required in non-white Europeans, in
children, and in adults over the age of 50. It is likely that the
model will need to be further refined for these age groups.
Our analysis used some features that are unchanged at
diagnosis (age at diagnosis and T1D-GRS), but other features
that were recorded at the time of organ donation and could
theoretically have been different at the time of diagnosis
(autoantibody status, BMI). Despite this, both BMI and
autoantibodies were discriminative. We hypothesize that the
discriminative power of these two variables will only be
enhanced by ascertainment at the time of diagnosis, further
improvingmodel performance. It is possible that, at diagnosis,
a model with only three variables (e.g. age at diagnosis, BMI
and one of either autoantibodies or T1D-GRS) will perform as
well as a four-variable model. It will be impossible to test this
in studies of organ donors, but we are currently testing this in a
prospective study assessing clinical features and biomarkers at
the time of diagnosis (ClinicalTrials.gov identifier:
NCT03737799). Our sample size limited our ability to test
if a model using all four variables was significantly superior to
a model using either T1D-GRS or autoantibodies (Fig. S1C–
F). Existing work suggest a three-variable model with either
autoantibodies or T1D-GRS is as good as a model with four
variables [9,13]. It is likely that the relative benefits of
autoantibody testing (a routinely available clinical test that is
very discriminative if taken at diagnosis) [8] and T1D-GRS
(time-independent and freely available in population bio-
banks) [30] will see them used differently depending on the
setting and availability. We did not have some potentially
relevant features at diagnosis, such as the presence of
ketoacidosis and pre-diagnosis weight loss, but to date these
have not been shown to be reliable discriminators of type 1
diabetes [4]. However, it will require larger studies with
detailed information at diagnosis, across diverse ages and
ethnicities, to fully elucidate the most accurate method and
combination of features to classify diabetes at diagnosis.
Despite the modest sample size of our study, limited by the
numbers of organ donors available worldwide, our study
provides robust histological evidence that a model combining
clinical features and biomarkers offers improved discrimina-
tion of type 1 diabetes, and that progression to C-peptide
2166
ª 2020 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK
DIABETICMedicine Histological validation of a type 1 diabetes model  A. L. J. Carr et al.
deficiency is an appropriate surrogate endpoint. Our study
therefore provides further evidence for a clinical diagnostic
model having utility to identify type 1 diabetes in clinical
practice, and for C-peptide as a surrogate outcome for
clinical studies in which histological classification is not
possible. Overall the study strengthens the evidence that a
clinical diagnostic model may aid classification in clinical
practice.
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